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A trial of chemotherapy in patients with osteosarcoma
(A report to the Medical Research Council by the their Working Party on
Bone Sarcoma)*
Summary Two hundred and thirty five patients with osteosarcoma, aged less than 40 years, and treated by
amputation or radiotherapy, were entered in a randomised trial of two forms of adjuvant chemotherapy. A
two drug regimen, namely vincristine 2 mg m-2 (maximum 2 mg) followed by methotrexate 200mgm-2, given
every three weeks, was compared with a three drug regimen, comprising the same vincristine-methotrexate
treatment, alternating every three weeks with doxorubicin 60mgm-2. Both regimens were continued for 54
weeks. Forty-one patients were excluded, most because of inadequate histology, leaving 194 patients for
analysis. One hundred and seventy of these had immediate amputation, 14 were treated by a policy of
radiotherapy, with surgery delayed for 9 months, provided no distant metastases had appeared, and 10 by a
policy of radiotherapy only. Patients have been followed-up for between 26 and 94 months after entry to the
trial. The 2- and 5-year survival rates were 48% and 27%. No significant difference in survival was observed
between the two regimens, but toxicity was less with the two drug regimen.
Although osteosarcoma is the commonest primary
malignant tumour of bone, the total number of
deaths registered annually in the United Kingdom
is less than 150. The 5-year survival rate 15 years
ago was about 20-25% (Sweetnam et al., 1971;
Price, 1967; Dahlin & Coventry, 1967). There was
little difference between the survival rate of patients
treated by immediate primary amputation and
those treated by the 'Cade policy', that is by
radiotherapy, with amputation delayed for 6 to 9
months, or abandoned if there was earlier evidence
of metastases (Cade, 1955).
Lung metastases occur early in the disease and
are present in about 80% of patients by 2 years
after presentation. It was thus realised that
improvement in survival rate would depend on
finding a method of eradicating the occult
pulmonary metastases. Response of lung metastases
to methotrexate used in high dosage with folinic
acid rescue (Jaffe et al., 1973) and to doxorubicin
(Cortes et al., 1972) was reported, followed by
preliminary reports of clinical advantage to patients
treated with these drugs as an adjuvant to surgery
(Jaffe et al., 1974; Cortes et al., 1974). The present
study began in February 1975.
Consideration was given initially to whether or
not a control group without adjuvant therapy
should be included in the trial. However, following
the two reports in 1974, many clinicians felt that it
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was not ethical to deny adjuvant treatment to any
patient. The suggestion was therefore abandoned.
Patients and methods
The object of the trial was to compare the efficacy
of two regimens of adjuvant cytotoxic drugs in the
control of occult lung metastases that might be
present in osteosarcoma patients treated by
amputation or by irradiation. The patients were
assessed regularly with regard to survival, the
appearance and progress of lung metastases and
performance status.
The diagnosis of osteosarcoma was confirmed by
biopsy; other mandatory investigations included
lung tomography, and a skeletal survey either by
radiograph or isotope scan. Patients could be
included in the trial if they were to be treated by
immediate amputation, by the Cade method, or by
radiotherapy alone. Patients excluded from the trial
were those over 40 years of age, those found to
have metastases or with a juxta-cortical
osteosarcoma, Paget's osteosarcoma or an
osteosarcoma arising in previously abnormal or
irradiated bone, and patients whose primary
tumour was in the skull or mandible. Patients
treated by local resection of the primary tumour
were not eligible. Patients with poor renal function,
impaired liver function, haematological or cardiac
abnormalities were also excluded.
An initial diagnosis was made by the referring
centre and patients were accepted on this basis for
the trial. Each centre sent biopsy samples to a
single reference pathologist (Prof. H.A. Sissons), in
order to ensure that the criteria for diagnosis were
consistent. Difficult diagnostic problems were
referred to the Cancer Research Campaign's Bone
Tumour Panel. All chest radiographs were reviewed
by the trial radiologist (the late Dr W. Park).
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The choice of drugs to be used was influenced by
the reports in the literature already quoted. It was
decided to compare two forms of adjuvant chemo-
therapy given intravenously:
1. A two drug regimen, consisting of:
Day 1 - Vincristine 2mgm 2 (maximum 2mg),
given half an hour before methotrexate
200mgm 2 as a bolus;
Day 2 - Folinic acid rescue, started 24h later.
This cycle was repeated every 3 weeks.
2) A three drug regimen consisting of:
Day I - Vincristine 2mgm 2 (maximum 2mg),
given half an hour before methotrexate
200mgm 2 as a bolus;
Day 2 - Folinic acid rescue, started 24h later;
Day 22 - Doxorubicin 60mgm 2
This cycle was repeated every 6 weeks.
The prescribed duration of chemotherapy in each
series was 54 weeks.
Two hundred patients were required to give an
80% chance of detecting a 20% difference in the 5-
year survival rate between the two treatment
groups. A randomisation scheme which stratified
patients by age, initial treatment to the primary
disease, and centre was adopted.
Patients were followed up by X-ray examination
every 6 weeks to 18 months, then every 3 months
to 5 years and then annually. Blood was examined
every 3 weeks for the first year, and then at the
same times as the X-ray examinations.
Results
Between February 1975 and July 1981, 235 patients
entered the trial from 52 centres within the UK and
Eire. Forty-one patients were ineligible, 32 because
of unconfirmed histology, 7 because of the presence
of overt metastases and one because of abnormal
Table I Initial characteristics in the two chemotherapy
groups
Regimen
Two drug Three drug Total
All patients 99 95 194
Sex Male 54 57 111
Female 45 38 83
Age-group Up to 10 14 12 26
(years) 11-15 43 35 78
16-39 42 48 90
Primary Amputation 86 84 170
trcatment Cade policy 8 6 14
Radiotherapy 5 5 10
renal function; one patient was withdrawn by the
centre concerned. There remained 194 eligible
patients.
Initial characteristics
Table I shows the sex, age and primary treatment
of the patients in the two chemotherapy groups.
The sites of the tumours in the two chemotherapy
groups are shown in Figure 1. The great majority
of patients (88%) underwent immediate amputation
of the affected limb, 7% were treated by the Cade
ig
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Figure 1 Sites of tumours in trial patients, according
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method, and 5% were treated by radiotherapy
alone.
Toxicity
The various known adverse reactions from
chemotherapy were monitored. The most serious
reaction was cardiotoxicity. None occurred in
patients on the two drug regimen, but in the three
drug regimen, 13 patients were affected, and 2
patients died of cardiomyopathy. Both had received
the full course of doxorubicin (540mgm 2) and
died within 6 months of completing the course.
Another patient developed heart failure 3 months
after finishing treatment on this regimen and
survived. Four patients were changed from the
three drug regimen during the course of treatment
because of ECG changes. Minor ECG changes,
that did not justify a change of treatment, were
noted in six other patients.
Nausea and vomiting occurred after adminis-
tering chemotherapy in most patients. Myelo-
suppression was mild, occurring in 33 patients (11
on the two drug and 22 on the three drug
regimen), with no instance of leucopaenia less than
3.0 x IO'1-'. As blood counts were only obtained
at the time of treatment rather than as true nadir
counts, this probably represents under-recording.
Alopecia occurred predominantly in patients on the
three drug regimen (80 patients out of 95 compared
with 14 out of 99 on the two drug regimen).
Neurotoxicity was noted in 18 patients; 2 were
given a reduced dose of vincristine and the
remainder continued on the regimen. Nine patients
were noted to have biochemical evidence of minor
liver toxicity and seven showed evidence of renal
toxicity. In all cases this was transient, requiring a
delay in treatment for one of the patients with liver
toxicity and 3 of those with renal toxicity. In
addition to the major difference in cardiotoxicity
noted above, there were more adverse reactions in
patients on the three drug regimen, including
myelosuppression and alopecia, and more severe
nausea and vomiting.
Compliance with trial chemotherapy
Deviations from the intended chemotherapy
occurred for various reasons. Seventy-nine patients
(43 on the two drug and 36 on the three drug
regimen) developed metastases during the treatment
period and in these treatment was changed.
Eighteen (9 from each group) refused to complete
the course. Intercurrent illness caused delay in
treatment for 11 on the two drug and 14 on the
three drug regimen. Toxicity resulted in 13 patients
on the two drug and 24 on the three drug regimen
deviating from the three weekly cycle; this ranged
from a delay in administering the drugs to a
complete removal from the therapy. These figures
are in line with the greater toxicity associated with
the three drug regimen.
Survivalfree oflung metastases, and survival
All 194 patients have been included in the survival
analyses. Because of the long intake period, patients
were followed for differing periods, and these
ranged from 26 to 94 months after entry.
The actuarial percentage surviving free of lung
metastases for 5 years was 25%. Figure 2 shows
that there was little difference between the lung
metastases-free survival curves in the two adjuvant
chemotherapy groups (logrank test x2=0.45,
P=0.50). The actuarial total percentage surviving
for 5 years was 27%, with little difference between
the chemotherapy groups (Figure 3, logrank test,
X2=0.86, P=0.36). The 2 year survival rate was 48%.
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Figure 2 Actuarial probability of survival free from
lung metastases against time in months since entry to
trial. Two drug group ( ); three drug group (----).
Activity grading
The effect of therapy on the quality of life was
monitored by periodic assessments of performance
status. The results for the two drug groups were
similar, about 75% of the survivors maintaining
normal or slightly restricted activity.
Prognosticfactors
Age at entry The percentages surviving free of
lung metastases in the three age categories are
shown in Figure 4. Logrank tests for the difference
between these curves, including a test for trend with
age, showed that the differences were not statis-
tically significant (Xverall=0.78, P=0.68, X2end=0.25,
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Figure 3 Actuarial probability of survival against
time in months since entry to trial. Two drug group
( ); three drug group (----).
P =0.62). Similar results were obtained when total
survival was examined.
Sex The lung metastases-free survival curves and
the total survival curves were similar for males and
females.
Site of tumour Most tumours were in the femur,
tibia or humerus, namely 103, 56 and 21
respectively. The overall difference between these
groups for survival free of lung metastases was not
significant (X2 = 1.30, P=0.48). Total survival gave a
similar result.
Time from onset of symptoms to trial entry This
was examined and found not to have a significant
effect on prognosis.
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Figure 4 Actuarial probability of survival free from
lung metastases against time in months since entry to
trial. Up to 10 years ( ); 11-15 years (----); 16-39
years (. )
Lung metastectomy
One hundred and thirty-five patients have
developed lung metastases. On development of lung
metastases further treatment was at the discretion
of the physician in charge, one possibility being
lung metastectomy, perhaps accompanied by more
aggressive chemotherapy or radiotherapy. Forty-
four patients have so far undergone metastectomy
(24 on the two drug regimen and 20 the three drug
regiman). Table II provides a summary of survival
results for all 44 patients. There was little difference
in overall pattern between the two drug regimens.
Approximately one-third of the patients had
multiple metastases at the time of lung
metastectomy, and those with a single metastasis
Table II Progress ofpatients undergoing metastectomy
Two drug Three drug
Metastases Metastases
Progress ofpatient Solitary Multiple Solitary Multiple Total
Alive and free from
metastases for more
than 1 year (21-41 months) 5 0 4 0 9
Alive and free from
metastases, observed
less than I year 0 1 1 0 2
Alive but developed
metastases 0 1 1 1 3
Died 10 7 6 7 30
Total 15 9 12 8 44
Vsu U.Ul l.
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fared better than the others (9/27 surviving more
than 1 year compared with 0/17).
Discussion
Entry to this trial was begun in 1975 and completed
in 1981, and all 194 eligible patients are included in
this analysis. The total 2- and 5-year survival rates
were 48% and 27%. These are lower than the 2-year
relapse free survival rates of 60-90%, falling to 40-
50% by 5 years, quoted from several adjuvant series
in North America (Eilber et al., 1978; Jaffe et al.,
1978; Marcove, 1978; Ettinger et al., 1979; Carter,
1980; Rosen et al., 1981, 1982). However, selection
criteria in the MRC trial were generally less
restrictive than in those studies. In particular only
conventional X-ray examination and tomography
were required to exclude lung metastases, so that
some patients with lung metastases now identifiable
by CT scanning may have been included.
The main results are the comparisons made
between the two drug and three drug regimens of
adjuvant chemotherapy, showing no difference in
lung metastases-free survival or in total survival.
However, toxicity was found to be substantially
greater in patients receiving the three drug
regimen. Cardiotoxicity was found in none of the 99
patients on the two drug regimen, compared with
13 of the 95 patients on the three drug regimen,
with two deaths from cardiomyopathy. Mild myelo-
suppression occurred in 11 and 22 patients,
and alopecia in 14 and 80 patients on the two and
three drug regimens respectively.
Another aspect of management of patients with
this disease is the treatment of lung metastases
developing during follow-up. In this trial there were
no survivors at 1 year among the 17 patients who
had thoracotomy for more than one lung
metastasis, but 9 out of 27 patients with a solitary
metastasis were alive at periods of 21 to 41 months
after thoracotomy. If other factors are favourable,
thoracotomy may therefore be justified for patients
with a single solitary metastasis.
There is a continued need for comparative trials
of adjuvant chemotherapy in osteosarcoma. The
fact that the survival rates in this study were lower
than in the non-randomised studies in North
America, referred to above, emphasises our lack of
knowledge of the real magnitude of improvement
afforded by use of adjuvant chemotherapy. Recently
Rosen and Nirenberg (1982) have claimed
remarkably good results from a protocol 'T-10',
consisting of high-dose methotrexate given pre-
operatively, followed by cis-platinum and
doxorubicin in addition to other drugs, in patients
whose tumours have responded poorly. Good
results with this complex regimen in clinical Stage I
osteosarcoma, in a randomised comparison with no
adjuvant chemotherapy, have now been reported by
Eilber and Eckhardt (1985). These findings provide
further motivation for conducting randomised
comparisons of adjuvant chemotherapy in this
disease.
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